Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the 40th Annual JP Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. The presentation will be accessible via a live webcast on the company's website, with a replay available for 90 days afterward. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, boasting a diverse portfolio aimed at high unmet medical needs. The company emphasizes efficient drug development to deliver safe and effective treatments urgently.

NOVATO, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the 40^th Annual JP Morgan Healthcare Conference on Monday, January 10, 2022 at 3:45 PM ET.

The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors  
Rob Anstey 
ir@ultragenyx.com  

Media  
Jeff Blake 
415-612-7784 
media@ultragenyx.com  

FAQ

When is Ultragenyx's presentation at the JP Morgan Healthcare Conference?

Ultragenyx's presentation is scheduled for January 10, 2022, at 3:45 PM ET.

Who will present at the JP Morgan Healthcare Conference for Ultragenyx?

Emil D. Kakkis, the CEO of Ultragenyx, will present at the conference.

How can I access the Ultragenyx presentation from the JP Morgan Healthcare Conference?

The presentation will be available via a live and archived webcast on Ultragenyx's website.

What is the focus of Ultragenyx Pharmaceutical Inc.?

Ultragenyx is focused on developing novel therapies for serious rare and ultra-rare genetic diseases.

How long will the Ultragenyx presentation be available for replay?

The replay of the presentation will be accessible for 90 days after the live event.